• LMO2–LDB1 Signaling in AML: Evidence and Limits

  2026-10-12

  A 2023 study links the LMO2/LDB1 transcriptional complex with proliferation and survival in several AML cell-line models. The findings support a mechanistic research hypothesis, but their clinical relevance remains limited by model choice, incomplete validation, and the absence of patient-treatment evidence.

• MG-132, Mitophagy, and Evidence Boundaries

  2026-10-12

  MG-132 (Z-LLL-al) is a cell-permeable proteasome inhibitor used in cancer research and apoptosis assay contexts, whereas the supplied Burkholderia pseudomallei study identifies a pathogen-driven mitophagy mechanism involving BipD and a host CUL3 ubiquitin-ligase complex. These findings are mechanistically related through protein-degradation biology but do not establish MG-132 as a tool, treatment, or validated intervention for that infection pathway.

• NETs and IL-36R in Psoriasis: Evidence and Limits

  2026-10-11

  A cautious overview of a 2024 study linking neutrophil extracellular traps, P2X7R–TLR signaling, and IL-36R activity in psoriasiform inflammation, with attention to model limitations, causal uncertainty, and the interpretive boundaries of fluorescence-based antibody detection.

• Proteasome Heterogeneity Across Breast Cancer Subtypes

  2026-10-10

  Kondakova and colleagues connect proteasome composition and activity with breast cancer subtype markers across transcriptomic, cellular, biochemical, and patient-tissue evidence. The study supports proteasome heterogeneity as a potential layer of subtype biology, while its observational design means the reported associations do not yet establish therapeutic causality.

• Modular mRNA Vaccines for SARS-CoV-2 Variants

  2026-10-09

  A 2026 Scientific Reports study describes TP2A, a modular mRNA vaccine candidate encoding secreted receptor-binding domains from SARS-CoV-2 wild type, Delta, and Omicron variants. In mice, TP2A produced early cross-variant antibody responses alongside interferon-γ-producing and cytotoxic T-cell responses, while its modular architecture suggests a framework for adapting antigen composition as viral lineages change.

• Gramine, CUL3–MTDH, and Ferroptosis in TNBC

  2026-10-09

  A 2026 study reports that gramine suppresses triple-negative breast cancer by engaging a previously underexplored CUL3–MTDH regulatory axis and promoting ferroptosis. Integrated target-binding, molecular, cellular, genetic, and xenograft evidence supports the mechanism, while model limitations mean the findings remain preclinical rather than clinically validated.

• ONX-0914 and Hippocampal Synaptic Plasticity

  2026-10-08

  Maltsev and colleagues examined how chronic inhibition of non-constitutive proteasomes affects two forms of hippocampal long-term potentiation in mice. Their results suggest that these proteasomes contribute selectively to tetanus-evoked, but not theta-burst-evoked, potentiation, with related changes in genes involved in glutamatergic signaling and synaptic plasticity.

• SIS3 and SMAD3: Reading TGF-β Evidence

  2026-10-08

  SIS3 is a selective Smad3 inhibitor for dissecting TGF-β signaling in fibrosis and cancer research. This evidence-focused guide connects SIS3’s mechanism with the super-enhancer and SMAD3 circuitry reported in early lung adenocarcinoma while clarifying translational limits.

• Disulfiram Beyond Proteasomes: Reading Pyroptosis Evidence

  2026-10-07

  Disulfiram is a dopamine β-hydroxylase inhibitor whose proteasome and gasdermin D biology spans cancer research and inflammation. This evidence-focused analysis separates established mechanisms from interpretation, using the NU6300 study to clarify how pyroptosis findings should be evaluated.

• Pomalidomide (CC-4047) in Myeloma Research

  2026-10-07

  Pomalidomide, also called CC-4047, is an immunomodulatory compound studied in multiple myeloma and related hematological malignancy research. Its strongest interpretive value is as a mechanistic hypothesis within genetically heterogeneous models, not as a standalone predictor of patient response.

• T7 RNA Transcription in Stress-Granule Research

  2026-10-06

  A source-grounded overview of how recent ribosome-profiling work clarifies G3BP and stress-granule effects on translation, and where T7 RNA polymerase transcription platforms may fit conceptually without substituting for evidence from cellular experiments.

• Firefly Luciferase mRNA: Evidence Guide

  2026-10-06

  Firefly Luciferase mRNA provides a light-based proxy for translated reporter expression. Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) combines a Photinus pyralis luciferase coding sequence with documented cap and nucleotide modifications, but product specifications should not be confused with independent comparative validation.

• Meropenem Trihydrate in Resistance Research

  2026-10-05

  A source-grounded overview of Meropenem trihydrate, carbapenem-resistance biology, metabolomics-based detection, research applications, evidence strength, and important limitations.

• O6-Benzylguanine: Evidence, Scope, and Limits

  2026-10-05

  A source-grounded overview of how O6-Benzylguanine relates to MGMT biology, what current evidence shows, how to interpret TMZ-resistance findings, and where the available evidence does not support broader clinical or experimental conclusions.

• HyperScribe T7 RNA Kit: Product Overview

  2026-10-04

  A concise, source-limited overview of the APExBIO HyperScribe™ T7 High Yield RNA Synthesis Kit, its documented identity, conceptual applications, and evidence limitations.

8487 records 1/566 page Next 12345 下5页 Last page